GoCART Coalition
Lymphoma Working Party (LWP)
Study type:
Study number:
Type of Stem Cell Treatment:
CAR T
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
CNS
Primary objective:
Primary endpoints:
1. Overall survival (OS): Time from CART to death from any cause
2. Progression-free survival (PFS): Time from CART to relapse, progression or death from any cause
Secondary endpoints:
3. Incidence of relapse (IR)
4. Non-relapse mortality (NRM)
1. Overall survival (OS): Time from CART to death from any cause
2. Progression-free survival (PFS): Time from CART to relapse, progression or death from any cause
Secondary endpoints:
3. Incidence of relapse (IR)
4. Non-relapse mortality (NRM)
Key inclusion criteria:
Country:
All EBMT member countries
Principal investigator:
Anna Ossami Saidy
EBMT Study coordinator:
Eva MICHEL
Study coordinator email:
eva.michel@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results